Sklerosierende Cholangitiden

Bergquist A, Ekbom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321–327

Björnsson E, Chari S, Silveira M et al (2011) Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 18: 198–205

Björnsson E, Olsson R, Bergquist A et al (2008) The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 134: 975–980

Boberg KM, Chapman RW, Hirschfield GM et al (2011) Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 54: 374–385

Broomé U, Olsson R, Lööf L et al (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610–615

Gelbmann CM, Rümmele P, Wimmer M et al (2007) Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Am J Gastroenterol 102: 1221–1229

Gelbmann CM, Schölmerich J (2007) Sekundär sklerosierende Cholangitis bei Intensivpatienten. Gastroenterologe 3: 45–50

Ghazale A, Chari ST, Zhang L et al (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134: 706–715

Gotthardt DN, Rudolph G, Klöters-Plachky P et al (2010) Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 71: 527–534

Hov JR, Keitel V, Laerdahl JK et al (2010) Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PloS One 5: e12403

Karlsen TH, Franke A, Melum E et al (2010) Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138: 1102–1111

Karlsen TH, Schrumpf E, Boberg KM (2010) Update on primary sclerosing cholangitis. Dig Liver Dis 42: 390–400

Kawakami H, Zen Y, Kuwatani M et al (2010) IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater’s ampulla and the bile duct. J Gastroenterol Hepatol 25: 1648–1655

Kulaksiz H, Heuberger D, Engler S, Stiehl A (2008) Poor outcome in progressive sclerosing cholangitis after septic shock. Endoscopy 40: 214–218

Lankisch TO, Metzger J, Negm AA et al (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology (Baltimore, Md.) 53: 875–884

Lindkvist B, Benito de Valle M, Gullberg B, Björnsson E (2010) Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52: 571–577

Melum E, Franke A, Schramm C et al (2011) Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 43: 17–19

Metzger J, Negm AA, Plentz RR et al (2012) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut (Epub ahead of print)

Negm AA, Schott A, Vonberg R-P et al (2010) Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc 72: 284–291

Ruemmele P, Hofstaedter F, Gelbmann CM (2009) Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 6: 287–295

Takuma K, Kamisawa T, Igarashi Y (2011) Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Curr Opin Rheumatol 23: 80–87

Tischendorf JJW, Hecker H, Krüger M et al (2007) Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 102: 107–114

Voigtländer T, Negm A, Schneider A et al (2012) Secondary sclerosing cholangitis in critically Ill patients: MELD score and renal function predict outcome. Endoscopy (in press)

Vosskuhl K, Negm AA, Framke T et al (2012) Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy 44: 48–52

Weismüller TJ, Lankisch TO (2011) Medical and endoscopic therapy of primary sclerosing cholangitis. Best practice and research. Clin Gastroenterol 25: 741–752

Weismüller TJ, Wedemeyer J, Kubicka S et al (2008) The challenges in primary sclerosing cholangitis–aetiopathogenesis, autoimmunity, management and malignancy. Journal of hepatology 48(Suppl 1): S38–57

Beuers U (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51: 237–267